Gossamer Bio, Inc. (NASDAQ:GOSS) Receives Average Recommendation of “Moderate Buy” from Analysts

Gossamer Bio, Inc. (NASDAQ:GOSS) has received a consensus rating of “Moderate Buy” from the six ratings firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $8.50.

GOSS has been the topic of several research reports. Wall Street Zen raised shares of Gossamer Bio from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a report on Wednesday, October 8th.

Gossamer Bio Stock Performance

Shares of GOSS opened at $2.52 on Tuesday. The stock has a 50 day simple moving average of $3.09 and a 200 day simple moving average of $2.57. Gossamer Bio has a 52-week low of $0.76 and a 52-week high of $3.87. The firm has a market capitalization of $583.28 million, a PE ratio of -3.65 and a beta of 1.92.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.02). Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. The company had revenue of $13.29 million during the quarter, compared to the consensus estimate of $6.32 million. Equities research analysts predict that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Gossamer Bio

Several hedge funds have recently made changes to their positions in the business. Corient Private Wealth LLC raised its holdings in Gossamer Bio by 8.9% during the second quarter. Corient Private Wealth LLC now owns 3,693,683 shares of the company’s stock worth $4,543,000 after acquiring an additional 302,200 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in Gossamer Bio by 720.2% in the first quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after purchasing an additional 825,047 shares in the last quarter. Acadian Asset Management LLC grew its stake in Gossamer Bio by 12.4% in the second quarter. Acadian Asset Management LLC now owns 7,146,022 shares of the company’s stock valued at $8,786,000 after purchasing an additional 787,909 shares in the last quarter. ProShare Advisors LLC acquired a new position in shares of Gossamer Bio during the 2nd quarter worth approximately $48,000. Finally, Drive Wealth Management LLC raised its stake in shares of Gossamer Bio by 52.7% during the 2nd quarter. Drive Wealth Management LLC now owns 25,474 shares of the company’s stock worth $31,000 after purchasing an additional 8,797 shares in the last quarter. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.